<font color='black' size='2' face='Tahoma, Arial, Helvetica, sans-serif'>
<div style="font-family:arial,helvetica;font-size:10pt;color:black">
<div id="AOLMsgPart_2_80b671c9-6f46-4251-ac82-44a01465cfcb">
<font face="Tahoma, Arial, Helvetica, sans-serif" color="black" size="2">
<div style="font-family:arial,helvetica;font-size:10pt;color:black">
<div id="AOLMsgPart_2_c5b07df2-5495-4585-b350-b97d6cc1ddb8">
<font face="Tahoma, Arial, Helvetica, sans-serif" color="black" size="2">
<div> I would like to bring to the attention of members the results of a <a href="http://www.cordsnetwork.org/wp-content/uploads/2014/05/FINAL-Leishmaniasis-Gap-Analysis-Report-and-Action-Plan_30-January-2016.pdf" rel="" target="_blank"> Leishmaniasis Gap Analysis Report and Action Plan</a> carried
out <font face="Tahoma, Arial, Helvetica, sans-serif" color="black" size="2"><font face="Tahoma, Arial, Helvetica, sans-serif" color="black" size="2"> by regional disease surveillance networks <a href="http://www.secids.com/" target="_blank">SECID/SEEHN</a>, <a href="http://www.mecidsnetwork.org/" target="_blank">MECIDS</a> and <a href="https://www.facebook.com/PakOneHealth/" target="_blank">Pak One Health </a></font></font>in Albania, Jordan and Pakistan during 2015 with the support of <a href="http://www.cordsnetwork.org/" target="_blank">CORDS</a> and the <a href="http://www.gatesfoundation.org/" target="_blank">Bill & Melinda Gates Foundation.</a><font face="Tahoma, Arial, Helvetica, sans-serif" color="black" size="2"><font face="Tahoma, Arial, Helvetica, sans-serif" color="black" size="2"> While
the situation is different in each of the countries, a common factor was the lack of access to safe and
effective treatment for those affected by both VL and CL. </font></font><br>
</div>
<div> <br>
</div>
<div style="clear:both">Jim Crilly<br>
crillyjim@a<font size="2">ol</font>.com<br>
</div>
</font>
</div>
</div>
</font>
</div>
</div>
</font>